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Abstract
Background: Pulmonary metastasis from prostate cancer is considered to be a late event, and patients can be
treated with chemotherapy or hormonal manipulation. However, there has been only a few reports on surgical
resection for pulmonary metastasis from prostate cancer.
Case Presentation: We present a surgical case of solitary pulmonary metastasis from prostate cancer. A 73-year-
old man underwent pelvic evisceration for prostate cancer. Histopathological examination revealed a poorly
differentiated adenocarcinoma with a sarcomatoid carcinoma component. During postoperative follow-up, chest
computed tomography showed a nodular shadow in the lung, and thoracoscopic wedge resection of the lung
was performed. Histopathological examination revealed a histological appearance similar to that of the prostate
sarcomatoid carcinoma. This is the first reported case of solitary pulmonary metastasis from prostate sarcomatoid
cancer.
Conclusion: Isolated pulmonary metastasis from prostate sarcomatoid cancer is extremely rare, but surgery could
be the treatment of choice.
Background
Although prostate cancer often metastasizes to the lung,
it usually metastasizes earlier to the bone [1]. Pulmonary
metastasis from prostate cancer often shows a diffuse
interstitial or multinodular pattern [2]. We report a rare
surgical case of solitary pulmonary metastasis from
prostate cancer.
Case Presentation
A 73-year-old man presented to the Department of
Urology in our hospital with a chief complaint of noc-
turia. His past medical history was unremarkable. Pelvic
computed tomography (CT) showed a large prostatic
mass invading the rectum and bladder. The serum pros-
tate-specific antigen (PSA) level was elevated to 14.37
ng/ml (normal range, 0.0-4.0 ng/ml). Prostate biopsy led
to a diagnosis of poorly differentiated adenocarcinoma.
In November 2008, the patient was started on maximum
androgen blockade. The serum PSA level markedly
declined, and has remained within the normal range
since December 2008. Pelvic magnetic resonance imaging
showed that the prostate decreased in size, but the mass
invading the rectum tended to enlarge (Figure 1A, B).
In April 2009, he underwent pelvic evisceration for the
prostate cancer (Figure 1C). Histopathological examina-
tion revealed a poorly differentiated Gleason 4/5 ade-
nocarcinoma in the prostate and an undifferentiated
sarcomatoid carcinoma consisting of fascicularly
arranged spindle cells in the area of posterior invasion
(Figure 2A-C). This undifferentiated carcinoma compo-
nent contained many multinucleated giant cells. Immu-
nohistochemically, the undifferentiated carcinoma was
positive for cytokeratin AE1/3, and negative for cyto-
keratin 7, cytokeratin 20, vimentin, and PSA (Figure
2D). During outpatient follow-up, the PSA level
remained within the normal range, but 3 months after
the pelvic evisceration, chest CT revealed a small nod-
ular shadow in S3b of the right lung (Figure 3A). At
the mediastinal window setting, the lung tumor
showed a density similar to that of large vessels (Figure
3B). Despite the resumption of maximum androgen
blockade, the tumor tended to enlarge. Positron emis-
sion tomography revealed an abnormal fluorodeoxy
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He was referred to our department for further evalua-
tion and treatment. He was otherwise in good health.
Blood chemistry data were unremarkable, and the
tumor markers SCC, CEA, SLX, NSE, and PSA were
all within normal limits.
Bronchoscopy was nondiagnostic, and thoracoscopic
wedge resection of the lung was performed in December
2009 (Figure 4A). Pleural disease was not observed dur-
ing thoracoscopy. The lung tumor, with a surface cov-
ered with the pleura, protruded into the pleural cavity
in a polypoid fashion (Figure 4A, B). Histopathological
examination revealed a histological appearance similar
to that of the pre-existing undifferentiated sarcomatoid
carcinoma, leading to a diagnosis of pulmonary metasta-
sis from the prostate cancer (Figure 4C, D). Many multi-
nucleated giant cells were also observed. As revealed by
strong contrast enhancement on a preoperative CT
scan, the tumor was histologically rich in microvessels.
Immunohistochemically, it was positive for cytokeratin
AE1/3, and negative for cytokeratin 7, cytokeratin 20,
vimentin, and PSA (Figure 4E).
His postoperative course was uneventful, and post-
operative adjuvant chemotherapy with cisplatin, ifosfa-
mide, and adriamycin was administered. At present, 10
months after lung surgery, he is free from recurrence.
Discussion
In various series, clinically apparent pulmonary metas-
tases were found in 5-27% of prostate cancer patients
[2,3]. These metastases are usually seen only after bone
metastases, and generally present in one of two basic
radiological patterns [1,4]. A diffuse interstitial pattern
representing lymphatic spread is the most common, but
a multinodular pattern representing hematological
spread may be seen on 8 to 20% of positive radiographs
[2,4]. Solitary pulmonary nodules have been reported
but are extremely rare [5,6].
Figure 1 Radiological and macroscopic findings of prostate cancer. A-B, Pelvic MRI showed an enlarged prostate invading the bladder
(arrow) and a polypoid mass invading the rectum (arrowhead)(A, T1-weighted sagittal view; B, T2-weighted axial view). C, Gross examination of
the resected specimen revealed an enlarged prostate invading the bladder (arrow) and polypoid mass invading the rectum (arrowhead).
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metastasis from prostate cancer [5,6]. Those two
reported patients underwent pulmonary resection for
metastatic adenocarcinoma. In the present patient, the
prostate cancer was what might be called a pleomorphic
carcinoma composed of a mixture of spindle cell carci-
noma and adenocarcinoma, an extremely rare histologi-
cal type in prostate cancer.
Since the sarcomatoid component that metastasized to
the lung was undifferentiated in this patient, it was
immunohistochemically negative for PSA. Unlike in
ordinary prostate cancer, the serum PSA level was not
correlated with the progression status of the sarcoma-
toid component. These findings suggest that the sarco-
matoid component did not produce PSA at all.
Hormone therapy had been effective for the adenocarci-
noma component; however, the sarcomatoid component
did not show sensitivity to hormone therapy. In addition,
the sarcomatoid component by itself might be more inva-
sive than normal adenocarcinoma. The tumor cells in the
posterior invasion area were predominant with the more
invasive sarcomatoid cancer. Thus, the sarcomatoid cancer
Figure 2 Histological findings of prostate cancer. A, The tumor was composed of a poorly differentiated Gleason 4/5 adenocarcinoma (lower
left of photograph) and an undifferentiated sarcomatoid carcinoma (upper right of photograph). B, The intraprostatic tumor showing a mixture
of cribriform structures and necrosis. C, The tumor in the area of posterior invasion. Arrows indicate multinucleated giant cells. D, Cytokeratin
AE1/3 immunostaining of the sarcomatoid carcinoma component.
Figure 3 CT findings of solitary pulmonary metastasis. A-B, After pelvic evisceration, chest CT revealed a small nodular shadow (A, Lung
window image; B, Mediastinal window image).
Goto et al. World Journal of Surgical Oncology 2010, 8:101
http://www.wjso.com/content/8/1/101
Page 3 of 5might have survived and metastasized to the lung. The
mainstay of treatment for patients with pulmonary metas-
tases, as with other sites of metastasis, is hormonal therapy
[2,7]. The pulmonary metastatic lesion in this patient
tended to enlarge during hormone therapy. This unre-
sponsiveness to medical therapy led us to consider surgical
treatment.
As is evident from the absence of PSA production and
unresponsiveness to hormone therapy, the sarcomatoid
component of a prostate tumor may have a biological
behavior different from that of prostate adenocarcinoma.
Solitary nodular metastasis of prostate cancer is extre-
mely rare, and might develop due to the biological dif-
ferences of sarcomatoid cancer. Thus, we believe that
surgical resection may be applicable for solitary pulmon-
ary metastasis of this sarcomatoid cancer.
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Figure 4 Pulmonary metastasis of prostate cancer. A, Gross appearance during thoracoscopic surgery. B, Gross appearance of the resected
specimen. C-D, Histology of the lung tumor. Arrows indicate multinucleated giant cells. E, Cytokeratin AE1/3 immunostaining of the lung tumor.
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